Article information
Full text is only aviable in PDF
References
[1.]
Clinical and Laboratory Standards Institute, 2005. Performance Standards for Antimicrobial Susceptibility Testing; 15 th information supplement. CLSI document M100-S15. Clinical and Laboratory Standards Institute, Wayne, PA.
[2.]
I.S. Kim, N.Y. Lee, C.S. Ki, et al.
Increasing prevalence of imipenem-resistant Pseudomonas aeruginosa and molecular typing of metallo-β-lactamase actamaseproducers in a Korean hospital.
Microb Drug Resist, 11 (2005), pp. 355-359
[3.]
U. Vurma-Rapp, F.H. Kayser, K. Hadorn, F. Wiederkehr.
Mechanism of imipenem resistance acquired by three Pseudomonas aeruginosa strains during imipenem therapy.
Eur J Clin Microbiol Infect Dis, 9 (1990), pp. 580-587
[4.]
A.C. Gales, P.L. Torres, D.S. Vilarinho, et al.
Carbapenem-resistant Pseudomonas aeruginosa outbreak in an intensive care unit of a teaching hospital.
Braz J Infect Dis, 8 (2004), pp. 267-271
[5.]
F. Dong, Y.S. Yu, T.T. Qu, et al.
Integron containing the VIM-2 metallo-β-lactamase gene among imipenem-resistant Pseudomonas aeruginosa strains from different Chinese hospitals.
J Clin Microbiol, 44 (2006), pp. 4242-4245
[6.]
F.C. Tenover, R.D. Arbeit, R.V. Goering, et al.
Interpreting chromosomal DNA restriction patterns produced by pulsed field gel electrophoresis: criteria for bacterial strain typing.
J Clin Microbiol, 33 (1995), pp. 410-419
[7.]
M.P. Crespo, N. Woodford, A. Sinclair, et al.
Outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-8, a novel metallo-β-lactamase, in a tertiary care center in Cali, Colombia.
J Clin Microbiol, 42 (2004), pp. 5094-5101
Copyright © 2011. Elsevier Editora Ltda.. All rights reserved
